Tyrosine kinase inhibitors in preclinical development

Investigational New Drugs

Volumn 17, Issue 3, 1999, Pages 213-226

  Levitt, Mark L ^a,b   Koty, Patrick P ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Epidermal growth factor receptor; Platelet derived growth factor receptor; Protein tyrosine kinase antagonists; Receptor protein tyrosine kinases; Review; Src tyrosine kinase

Indexed keywords

ANGIOGENESIS INHIBITOR; BENZYLIDENE DERIVATIVE; CELL SURFACE RECEPTOR; CINNAMIC ACID DERIVATIVE; EMODIN; GENISTEIN; ISOFLAVONE; METHOTREXATE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; QUINONE DERIVATIVE; TYRPHOSTIN; UNINDEXED DRUG;

ADVANCED CANCER; AUTOPHOSPHORYLATION; CANCER CHEMOTHERAPY; CANCER INHIBITION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; PROTEIN-TYROSINE KINASES; QUINOLINES; QUINONES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0033392002     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006372102543     Document Type: Review

References (134)

1. Karin M, Hunter T: Transcriptional control by protein phosphorylation: signal transmission from the cell surface to the nucleus. Curr Biol 5: 747-757, 1995
2. Hill CS, Treisman R: Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell 80: 199-211, 1995
3. Cooper GM: Oncogenes and growth factors. In: Oncogenes, Chap. 11, pp. 163-173, Boston: Jones and Bartlett Publishers, 1990
4. Kolibaba KS, Druker BJ: Protein tyrosine kinases and cancer. Biochem Biophys Acta 1333: F217-248, 1997
5. Porter AC, Vaillancourt RR: Tyrosiae kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 17: 1343-1352, 1998
6. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212, 1990
7. Schlessinger J, Ullrich A: Growth factor signaling by receptor tyrosine kinases. Neuron 9: 383-391, 1992
8. Fantl WJ, Johnson DE, Williams LT: Signalling by receptor tyrosine kinases. Annu Rev Biochem 62: 453-481, 1993
9. Heldin C-H: Dimerization of cell surface receptors in signal transduction. Cell 80: 213-223, 1995
10. Goldman R, Ben Levy R, Peles E, Yarden Y: Heterodimerization of the erbB-1 and erba-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry 29: 11024-11028, 1990.
11. Wada T, Qian X, Greene MI: Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 61: 1339-1347, 1990
12. Groner B, Gouilleux F: Prolactin-mediated gene activation in mammary epithelial cells. Curr Opin Genet Dev 5: 587-594, 1995
13. Argetsinger LS, Carter-Su G: Mechanism of signaling by growth hormone receptor. Physiol Rev 76: 1089-1107, 1996
14. Carter-Su C, Schwartz J, Smit LS: Molecular roechanism of growth hormone action. Annu Rev Physiol 58: 187-207, 1996
15. Cambier JC: Signal transduction by T- and B-cell antigen receptors: converging structures and concepts. Curr Opin Immunol 4: 257-264, 1992
16. Keegan AD, Paul WE: Multichain immune recognition receptors: similarities in structure and signaling pathways. Immunot Today 13: 63-68, 1992
17. Weiss A, Littman DR: Signal transduction by lymphocyte antigen receptors. Cell 76: 263-274, 1994
18. Collette Y, Olive D: Non-receptor protein kinases as immune targets of viruses Immunol. Today 18: 393-400, 1997
19. Kishimoto T, Taga T, Akira S: Cytokine signal transduction. Cell 76: 253-262, 1994
20. Mui A, Miyajima A: Cytokine receptors and signal transduction. Prog Growth Factor Res 5: 15-35, 1994
21. Ihle JN: Cytokine receptor signalling. Nature 377: 591-594, 1995
22. Taniguchi T: Cytoldne signaling through nonreccptor protein tyrosine kinases. Science 268: 251-255, 1995
23. Wells J, de Vos A: Hematopoietic receptor complexes. Annu Rev Biochem 65: 609-634, 1996
24. Chan C-J, Geahlen RL: Protdn-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Net Prod (Lloydia) 55: 1529-1560, 1992
25. Smith JA, Francis SH, Corbin JD: Autophosphorylation: a salient feature of protein kinases. Mel Cell Biochem 127-128: 51-70, 1993
26. Bolen JB: Nonreceptortyrosine protein kinases. Oncogene 8: 2025-2031, 1993
27. Hunter T: Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell 80: 225-236, 1995
28. Tonks NK, Neel BG: From form to function: signaling by protein tyrosine phosphatases. Cell 87: 365-368, 1996
29. Matozaki T, Kasuga M: Roles of protein-tyrosine phosphatases in growth factor signalling. Cell Signal 8: 13-19, 1996
30. Pani G, Siminovitch KA: Protein tyrosine phosphatase roles in the regulation of lymphocyte signaling. Clin Immunol Immunopathol 84: 1-16, 1997
31. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J, Downward J, Mayes ELV, Whittle N, Waterfield MD, Seeberg PH: Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309: 418-425, 1984
32. Besmer P, Lader E, George PC, Bergold PJ, Qiu FH, Zuckerman EE, Hardy WD: A new acute transforming feline retrovirus with fms homology specifies a C-terminally truncated version of the c-fms protein that is different from SM-feline sarcoma virus v-fms protein. J Virol 60: 194-203, 1986
33. Smith DR, Vogt PK, Hayman MJ: The v-sea oncogene of avian erythroblastosis retrovirus S13: another member of the protein-tyrosine kinase gene family. Proc Natl Acad Sci USA 86: 5291-5295, 1989
34. van Daalen Wetters T, Hawkins SA, Roussel MF, Sherr CJ: Random mutagenesis of CSF-1 receptor (FMS) reveals multiple sites for activating mutations within the extracellular domain. EMBO J 11: 551-557, 1992
35. Bargmann CI, Weinberg RA: Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J 7: 2043-2052, 1988
36. Weiner DB, Liu J, Cohen JA, Williams WV, Greens MI: A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature 339: 230-231, 1989
37. Zong CS, Poon B, Chen J, Wang L-H: Molecular and biochemical bases for activation of the transforming potential of the proto-oncogene c-ros. J Virol 67: 6453-6462, 1993
38. Shu HK, Pelley RJ, Kung H-J: Tissue-specific transformation by epidermal growth factor receptor: a single point mutation within the ATP-binding pocket of the erbB product increases its intrinsic kinase activity and activates its sarcomagenic potential. Proc Natl Acad Sci USA 87: 9103-9107, 1990
39. McDonough SK, Larsen S, Brodey RS, Stock ND, Hardy Jr. WD: A transmissible feline fibrosarcoma of viral origin. Cancer Res 31: 953-956, 1971
40. Nowell PC, Hungerford DA: Chromosome studies on normal and leukemic human leukocytes. J Nat Cancer Inst 25: 85-109, 1960
41. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G: Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36: 93-99, 1984
42. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G: Structural organization of the bcr gene and its role in the Ph′ translocation. Nature 315: 758-761, 1985
43. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D: The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233: 212-214, 1986
44. Davis RL, Konopka JB, Witte ON: Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties. Mol Cell Biol 5: 204-213, 1985
45. Lugo T, Pendergast A-M, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247: 1079-1082, 1990
46. Hughes TP, Goldman JM: In: Hoffman R, Benz Jr. EJ, Shatil SJ, Furie B, Cohen HJ, Silberstein LE (Eds) Hematology: Basic Principles and Practice, 2nd ed., Churchill Livingstone, New York, pp. 1142-1159, 1995
47. Shin DM, Ro JY, Hong WK, Hittelman WN: Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54: 3153-3159, 1994
48. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K: Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res 50: 7077-7080, 1990
49. Gorgoulis V, Aninos D, Mikou P, Kanavaros P, Karameris A, Joardanoglu J, Rasidakis A, Veslemes M, Ozanne B, Spandidos DA: Expression of EGF, TGF-alpha and EGFR in squamous cell lung carcinomas. Anticancer Res 12: 1183-1187, 1992
50. Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali IU: Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52: 4550-4553, 1992
51. Maxwell M, Naber SP, Wolfe HJ, Galanopoulos T, Hedley-Whyte ET, Black PM, Antoniades HN: Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. J Clin Invest 86: 131-140, 1990
52. Hermanson M, Funa K, Hartman H, Claesson-Welsh L, Heldin C-H: Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52: 3213-3229, 1992
53. Ross JS, Fletcher JA: The HER2/neu oncogene in breast cancer: prognostic factor, predictive factor and target for therapy. Stem Cells 16: 413-428, 1998
54. Talamonti MS, Roh MS, Curley SA, Gallick GE: Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 91: 53-60, 1993
55. Mustonen T, Alitalo K: Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 1251: 895-898, 1995
56. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995
57. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VECF) and its receptors. FASEB J 13: 9-22, 1999
58. Levitzki A: Signal-transduction therapy. A novel approach to disease management. Eur J Biochem 226: 1-13, 1994
59. Gazit A, Yaish P, Gilon C, Levitzki A: Tyrphostins I; synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem 32: 2344-2352, 1989
60. Gazit A, Osherov N, Posner I, Yaish P, Poradosu E, Gilon C, Levitzki A: Tyrphostins II: hetercyclic and -substituted benzylide-nemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. J Med Chem 34: 1897-1907, 1991
61. Shiraishi T, Owada MK, Tatsuka M, Fuse Y, Kiyoshi W, Kakunaga T: A tyrosine-specific protein kinase inhibitor, alpha-cyano-3-ethoxy-4-hydroxy-5-phenylthiomethyl-cinnamide, blocks the phosphorylation of tyrosine kinase in intact cells. Jpn J Cancer Res 81: 645-652, 1990
62. Levitzki A, Gazit A: Tyrosine kinase inhibition: An approach to drug development. Science 267: 1782-1788, 1995
63. Klohs WD, Fry DW, Kraker AJ: Inhibitors of tyrosine kinase. Curr Opin Oncol 9: 562-568, 1997
64. Kelloff GJ, Fay JR, Steele VE, Lubet RA, Boone CW, Crowell JA, Sigman CC: Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cane Epidem Biomark Prev 5: 657-666, 1996
65. Stavric V: Quercetin in our diet: from potent mutagen to probable anticarcinogen. Clin Biochem 27: 245-248, 1994
66. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262: 5592-5595, 1987
67. Kim H, Peterson TG, Barnes S: Mechanisms of activation of the soy isoflavone genistein: emerging role for its effects via transforming growth factor beta signaling pathways. Am J Clin Nutr 68: 1418S-1425S, 1998
68. Peterson TG, Coward L, Kirk M, Falany CN, Barnes S: The role of metabolisn in mammary epithelial cell growth inhibition by the isoflavones genistein and biochanin A. Carcinogenesis 17: 1861-1869, 1996
69. Xuan Y, Hacker MP, Tritton TR, Bhushan A: Modulation of methotrexate resistance by genistein in murine leukemia L1210 cells. Oncol Rep 5: 419-421, 1998
70. Uckun FM, Narla RK, Jun X, Zeren T, Venkatachalam T, Waddick KG, Rostostev A, Myers DE: Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells. Clin Cancer Res 4: 901-912, 1998
71. Lei W, Mayotte JE, Levitt ML: EGF dependent and independent programmed cell death pathways in NCI-H596 non-small cell lung cancer cells. Biochem Biophys Res Communications 245: 939-945, 1998
72. Uckun FM, Narla RK, Zeren T, Yanishevski Y, Myers DE, Waurzyniak B, Ek O, Schneider E, Messinger Y, Chelstrom LM, Gunther R, Evens W: In vivo toxicity, pharmacokinetics and anticancer activity of genistein linked to recombinant human epidermal growth factor. Clin Cancer Res 4: 1125-1134, 1998
73. Theodorescu D, Laderoute KR, Calaoagan JM, Guilding KM: Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression. Int J Cancer 78: 775-782, 1998
74. Yan C, Han R: Suppression of adhesion-induced protein tyrosine phosphorylation decreases invasive and metastatic potentials of B16-BL6 melanoma cells by protein tyrosine kinase inhibitor genistein. Invasion Metastasis 17: 189-198, 1997
75. Wei H, Bowen R, Zhang X, Lebwohl M: Isoflavone genistein inhibits the initiation and promotion of two-stage skin carcinogenesis in mice. Carcinogenesis 19: 1509-1514, 1998
76. Ahmad N, Gali H, Javed S, Agarwal R: Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression. Biochem Biophys Res Commun 247: 294-301, 1998
77. Cushman M, Zhu H, Geahlen RL, Kraker AJ: Synthesis and biochemical evaluation of a series of aminoflavones as potential inhibitors of protein-tyrosine kinases p56lck, EGFr and p60v-src. J Med Chem 37: 3353-3365, 1994
78. Fry DW, Kraker AJ, McMichael A, Ambrose LA, Nelson JM, Leopold WR, Connors RW, Bridges AJ: A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265: 1093-1095, 1994
79. Osherov N, Levitzki A: Epidefmal-gtowth-factor-dependent activation of the src-family kinases. Eur J Biochem 225: 1047-1053, 1994
80. Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, McNamara DJ, Nelson JM, Sherwood V, Smaill JB, Trumpp-Kallmeyer S, Dobrusin EM: Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci USA 95: 12022-12027, 1998
81. Woodburn JR, Baarker AJ, Gibson KH, Ashton SE, Wakeling AE, Curry BJ, Scarlett L, Henthorn LR: ZD1839, an epidennal growth factor tyrosine kinase inhibitor selected for clinical development. Proc Annu Meet Am Assoc Cancer Res 38: A4251, 1997
82. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, Vaidya MP, Iwata K: Therapy of human carcinomas in athymic mice by inhibition of EGF receptor mediated signal transduction with CP-358774: Dynamics of receptor inhibition and antitumor effects. Proc Annu Meet Am Assoc Cancer Res 38: A4249, 1997
83. Iwata K, Miller PE, Barbacci EG, Arnold L, Doty J, DiOrio CI, Pustilnik LR, Reynolds M, Thelemann A, Sloan D, Moyer JD: CP-358,774: A selective EGFR kinase inhibitor with potent antiproliferative activity against HN5 head and neck tumor cells. Proc Annu Meet Am Assoc Cancer Res 38: A4248, 1997
84. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveau M, Pollack VA, Pustilnik LR, Reynolds MM, Sloan D, Theleman A, Miller P: Induction of apoptosis and cell cycle arrest by CP-358,774, and inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57: 4838-4848, 1997
85. Hartman RR, Rimoldi D, Lejeune FJ, Carrel S: Cell differentiation and cell-cycle alterations by tyrosine kinase inhibitors in human melanoma cells. Melanoma Res 7: S27-S33, 1997
86. Modjtahedi H, Affleck K, Stubberfield C, Dean C: EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. Int J Oncol 13: 335-342, 1998
87. Kunkel MW, Hook KE, Howard CT, Przbranowski S, Roberts BJ, Elliott WL, Leopold WR: Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Invest New Drugs 13: 295-302, 1996
88. Jones HE, Dutkowski CM, Barrow D, Harper ME, Wakeling AE, Nicholson RI: New EGF-R selective tyrosine kinase inhibitor reveals variable grwoth responses in prostate carcinoma cell lines PC-3 and DU-145. Int J Cancer 71: 1010-1018, 1997
89. Woodburn JR, Barker AJ, Wakeling AE, Valcaccia BE, Cartlidge SA, Davies DH: 6-Amino-4-(3-methylphenylamino)-quinazoline: an EGF receptor tyrosine kinase inhibitor with activity in a range of human tumor xenografts. Proc Annu Meet Am Assoc Cancer Res 37: A2465, 1996
90. Baguley BC, Marshall ES, Holdaway KM, Rewcastle GW, Denny WA: Inhibition of growth of primary human tumour cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinases. Eur J Cancer 34: 1086-1090, 1998
91. Uehara Y, Murakami Y, Suzukake-Tsuchiya KK, Moriya Y, Sano H, Shibata K, Omura S: Effects of herbimycin derivatives on src oncogene function in relation to antitumor activity. J Antibiot 41: 831-834, 1988
92. Billis WM, White BA: Effects or the protein tyrosine kinase inhibitor, herbimycin A, on prolactin gene expression in GH3 and 235-1 pituitary tnmor cells. Biochem Biophys Acta 1358: 31-38, 1997
93. Murakami Y, Fukazawa H, Mizuno S, Uehara Y: Effect of herbimycin A on tyrosine kinase receptors and platelet derived growth factor (PDGF)-induced signal transduction. Biol Pharm Bull 21: 1030-1035, 1998
94. Mimnaugh EG, Chavany C, Neckers L: Polyubiquitination and proteosomaldegradation of the p185c-erbB2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 271: 22796-22801, 1996
95. Hartmann F, Horak EM, Cho C, Lupu R, Bolen JB, Stetler-Stevenson MA, Pfreundschuh M, Waldmann TA, Horak ID: Effects of the tyrosine-kinase inhibitor geldanamyn on ligand-induces Her-2/neu activation, receptor expression and proliferation of Her-2-positive malignant clees. Int J Cancer 70: 221-229, 1997
96. Brunton VG, Lear MJ, McKeown P, Robins DJ, Workman P: Synthesis and antiproliferative activity of tyrphostins containing quinolone moieties. Anticancer Drug Res 11: 463-483, 1996
97. Orfi L, Kokosi J, Szasz G, Kovesdi L, Mak M, Teplan I, Keri G: Heterocondensed quinazolones: synthesis and protein-tyrosine kinase inhibitory activity of 3,4-dihydro-1H,6H-[1,4]oxazino-[3,4-b]quinazolin-6-one derivatives. Bioorg Med Chem 4: 547-551, 1996
98. Rewcastle GW, Palmer BD, Thompson AM, Bridges AJ, Cody DR, Zhou H, Fry DW, McMichael A, Denny WA: Tyrosine kinase inhibitors: 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyfosine kinase function of the epidermal growth factor receptor. J Med Chem 39: 1823-1835, 1996
99. Rewcastle GW, Murray DK, Elliott WL, Fry DW, Howard CT, Nelson JM, Roberts BJ, Vincent PW, Showalter HD, Winters RT, Denny WA: Tyrosine kinase inhibitors: 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidin (PD158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors. J Med Chem 41: 742-751, 1998
100. Brown C, McNeil L, Mendelsohn J, Fry DW: An epidermal growth factor (EGF) receptor specific tyrosine kinase inhibitor blocks receptor activation and inhibits growth in squamous carcinoma of the cervix. Proc Annu Meet Am Assoc Cancer Res 38: A3151, 1997
101. Slintak V, Keller PR, Rewcastle GW, Denny WA, Fry DW: PD158780 is a potent inhibitor of heregulin-dependent tyrosine pbosphorylation of erbB2, erbB3 and erbB4. Proc Annu Meet An Assoc Cancer Res 38: A3145, 1997
102. Elliott WL, Fry DW, Vincent PW, Roberts BJ, Howard CT, Slintak V, Nelson JM, Hook KE, Showalter HD, Winters TR, Denny WA, Thompson AM: In vitro and in vivo activity of 4-anilinopyridopyrimidine EGF family specific tyrosine kinase inhibitors. Proc Annu Meet Ant Assoc Cancer Res 38: A3144, 1997
103. Klutchko SRR, Hamby JM, Boschelli DH, Wu Z, Kraker AJ, Amar AM, Hartl BG, Shen C, Klohs WD, Steinkampf RW, Driscoll DL, Nelson JM, Elliott WL, Roberts BJ, Stoner CL, Vincent PW, Dykes DJ, Panek RL, Lu GH, Major TC, Dahring TK, Hallak H, Bradford LA, Showalter HD, Doherty AM: 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. J Med Chem 41: 3276-3292, 1998
104. Lyndon NB, Mett H, Mueller M, Beckker M, Cozens RM, Stover D, Daniels D, Taxler P, Buchdunger E: A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo. Int J Cancer 76: 154-163, 1998
105. Traxler PM, Furet P, Mett H, Buchdunger E, Meyer T, Lydon N: 4-(Phenylamino)pyrrolopyrimidines: Potent and selective ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem 39: 2285-2292, 1996
106. Umezawa H, Imoto M, Sawa T, Isshiki K, Matsuda N, Uchida T, Iinuma, H, Hamada M, Takeuchi T: Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3. J Antibiot 39: 170-173, 1986
107. Levitzki A: Tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. PASEB J 6: 3275-3283, 1992
108. Gazit A, Osherov N, Posner L, Bar-Sinai A, Gilon C, Levitski A: Tyrphostins: Structure-activity relationship studies of alpha-substituted benzylidenemalononitrile 5-S-aryltyrphostins. J Med Chem 36: 3556-3564, 1993
109. Simizu S, Umezawa K, Takada M, Arber N, Imoto M: Induction of hydrogen peroxide production and Bax expression by caspase-3(-like) proteases in tyrosine kinase inhibitor-induced apoptosis in human small cell lung carcinoma cells. Exp Cell Res 238: 197-203, 1998
110. Osherov N, Gazit A, Gilon C, Levitski A: Selective inhibition of the epidermal growth factor and HER-2/neu receptors by tyrphostins. J Biol Chem 268: 11134-11142, 2993
111. Novogrodsky A, Weisspapir M, Patya M, Meshorer A, Vanichkin A: Tyrphostin 4-nitrobenzylidene malononitrile reduces chemotherapy toxicity without impairing efficacy. Cancer Res 58: 2397-2403, 1998
112. Liang BC, Ullyatt E: Chemosensitization of glioblastoma cells to bis-dichloroethyl-nirosourea with tyrphostin AG17. Clin Cancer Res 4: 773-781, 1998
113. Bartlett JM, Brunton V, Morrison V, Cooke TG: EGF and c-erbB-2 selective tyrosine kinase inhibitors block EGF mediated proliferation and reduce EGF, c-erbB2 and MAP kinase activation in gastric cancer cell lines. Br J Cancer 73: 7, 1996
114. Tsai CM, Levitski A, Wu LH, Chang KT, Cheng CC, Gazit A, Perng RP: Enhancement of chemosensitivity by tyrphostin AG825 in high-pi85(neu) expressing non-small cell lung cancer cells. Cancer Res 56: 1068-1074, 1996
115. Zhang L, Hung MC: Sensitization of HER-2/neuoverexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase: inhibitor emodin. Oncogene 12: 571-576, 1996
116. Zhang L, Lau YK, Xi L, Hong RL, Kim DS, Chen CF, Hortobagyi GN, Chang C, Hung MC: Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties. Oncogene 16: 2855-2863, 1998
117. Han Y, Caday CG, Umezawa K, Nanda A: Preferential inhibition of glioblastoma cells with wild-type epidermal growth factor receptors by a novel tyrosine kinase inhibitor ethyl-2,5-dihydroxycinnamate. Oncol Res 9: 581-587, 1997
118. Kobari M, Kullenberg B, Bjorkman A, Matsuno S, Ihse I, Axelson J: The inhibitory effect of an EGF receptor-specific tyrosine kinase inhibitor on pancreatic cancer cell lines was more potent than inhibitory antibodies against the receptors for EGF and IGF I. Int J Pancreatol 24: 85-95, 1998
119. Westermark B, Heldin CH: Platelet-derived growth factor: Structure, function and implications in normal and malignant cell growth. Acta Oncol 32: 101-105, 1993
120. Klohs W, Steinkampf R, Driscoll D, Klutchko S, Hamby J, Lu G, Vincent P, Roberts B, Elliott W: Characterization of PDGF tyrosine kinase inhibitors in in vitro and in vivo tumors. Proc Annu Meet Am Assoc Cancer Res 38: A4244, 1997
121. Buchdunger E, Zimmermann J, Mett H, Meyer T, Mueller M, Regenass U, Lyndon NB: Selective inhibition of the platelet derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylamino-pyrimidine class. Proc Natl Acad Sci USA 92: 2558-2562, 1995
122. Yoneda J, Fidler IJ, Kumar R, Bucana CD, Killion JJ, Radinskky R: Inhibitory effect of platelet derived growth factor receptor (PDGF-R) tyrosine kinase (TK) inhibitor, CGP 53716, on tumor stroma formation, angiogenesis, and orthotopic growth of human lung carcinoma cells in nude mice. Proc Annu Meet Am Assoc Cancer Res 38: A4245, 1997
123. Kovalenko M, Gazit A, Bohmer A, Rorsman C, Ronnstrand L, Heldin CH, Waltenberger J, Bohmer FD, Levitzki A: Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res 34: 6106-6114, 1994
124. Showalter HD, Sercel AD, Leja BM, Wolfnagel CD, Ambroso LA, Elliott WL, Fry DW, Kraker AJ, Howard CT, Lu GH, Moore CW, Nelson JM, Roberts BJ, Vincent PW, Denny WA, Thompson AM: Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2′-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur cogeners. J Med Chem 40: 413-426, 1997
125. Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK, Hubbard SR, Schlessinger J: Structure of the tyrosine kinase domain of the fibroblast factor receptor in complex with inhibitors. Science 276: 955-960, 1997
126. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Shawver LK: Flk-1 as a target for tumor growth inhibition. Cancer Res 56: 3540-3545, 1996
127. Fong TAT, McMahon G, Kim Y, Sun L, Tang C, Chen J, Sutton B, Schreck R, Smolich B, Jacobs J, Shawver LK: Small molecule inhibitors of Flk-1 suppress subcutaneous growth of muhiple tumor types, inhibit tumor angiogenesis, and provide attenuation of metastasis. Proc Annu Meet Am Assoc Cancer Res 38: A1789, 1997
128. Wood J, Mett H, Stover D, Buchdunger E, Siemeister G, Martiny-Baron G, Marme D, Fabbro D: CGP41251, an inhibitor of VEGF receptor tyrosine kinases. Proc Annu Meet Am Assoc Cancer Res 38: A1787, 1997
129. Kraker AJ, Moore CW, Amar AM, Shen CS, Nelson J, Slintak V, Fry DW, Lu G, Panek R, Klutchko S, Hamby J: Cytotoxicity and phosphotyrosine effects of c-src kinase inhibition by substituted pyridopyrimidine tyrosine kinase inhibitors in human colon carcinoma cell lines. Proc Annu Meet Am Assoc Cancer Res 38: A4247, 1997
130. Krystal GW, DeBerry CS, Linnekin D, Litz J: Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1. Cancer Res 58: 4660-4666, 1998
131. Krystal GW, Carlson P, Litz J: Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrphostins. Cancer Res 57: 2203-2208, 1997
132. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA, Connelly PA: Discovery of a novel, potent, and src-family selective tyrosine kinase inhibitor. J Biol Chem 271: 495-701, 1996
133. Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff N, Vaught JL, Murakata C, Djakiew D, Lamb J, Bova S, George D, Isaacs JT: Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res 4: 1887-1898, 1998
134. Dionne CA, Camoratto AM, Jani JP, Vaught J, Murakata C, Djakiew D, Bova S, George D, Isaacs JT: Inhibition of prostate tumor growth by the trk-selective tyrosine kinase inhibitor, CEP-751 (KT-6587). Proc Annu Meet Am Assoc Cancer Res 38: A4254, 1997